Cynata Therapeutics (ASX:CYP) Presentation, FNN Investor Event, October 2017, Sydney

Company Presentations

Last Movement
$1.070 $0.000 0.00%
Data Source:
Last Updated: 11/12/2019 3:01 PM

Cynata Therapeutics Limited (ASX:CYP) Managing Director and CEO Dr Ross Macdonald provides an overview of the company's stem cell manufacturing platform, commercialisation pathway and strategy.

Key points:

 - Developing a novel therapeutic stem cell (MSC) technology: CymerusTM
 - World-first Phase I clinical trial commenced in Graft vs Host disease (GvHD); sites in UK and Australia
 - Strategic partnership with Japanese regenerative medicine company, Fujifilm Corporation
 - License option agreement with apceth GmbH & Co. KG for several disease target areas - Strong balance sheet: cash runway into 2019 based on current projections
 - Compelling preclinical data from a range of animal proof-of-concept studies in asthma, heart attack and critical limb ischemia.
 - Broad commercial potential in a range of diseases including stroke, heart disease and osteoarthritis
 - Regenerative medicine industry expected to grow to over $53.7 billion by 2021.